Beximco Pharmaceuticals PLC. (AIM:BXP)
London
· Delayed Price · Currency is GBP · Price in GBX 42.00
0.00 (0.00%)
At close: Dec 5, 2025
AIM:BXP Revenue
Beximco Pharmaceuticals PLC. had revenue of 12.30B BDT in the quarter ending December 31, 2024, with 12.80% growth. This brings the company's revenue in the last twelve months to 46.34B, up 11.26% year-over-year. In the fiscal year ending June 30, 2024, Beximco Pharmaceuticals PLC. had annual revenue of 44.39B with 13.05% growth.
Revenue (ttm)
46.34B BDT
Revenue Growth
+11.26%
P/S Ratio
0.98
Revenue / Employee
41.30M BDT
Employees
1,122
Market Cap
301.45M GBP
Revenue Chart
* This company reports financials in BDT.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 44.39B | 5.12B | 13.05% |
| Jun 30, 2023 | 39.27B | 4.60B | 13.26% |
| Jun 30, 2022 | 34.67B | 5.18B | 17.55% |
| Jun 30, 2021 | 29.49B | 3.88B | 15.16% |
| Jun 30, 2020 | 25.61B | 2.80B | 12.25% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Beximco Pharmaceuticals PLC. News
- 1 year ago - Small Cap Stocks: Indus Gas, VAST Resources, Beximco - The Armchair Trader